CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment

CAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies.

Subsidie
€ 2.733.931
2023

Projectdetails

Introduction

Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME).

Project Overview

Combining innovative methods of genome editing, chemistry, and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME.

Genetic Rewiring

Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related “Driver” promoters to downregulate “Target” genes that cause exhaustion. Proprietary technology enables specific replacement of the “Driver” gene without risking off-target mutations.

Advantages of the Approach

Further advantages of combined insertion and silencing are:

  1. The ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues.
  2. Multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles.

Gene Delivery Platform

These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large-scale GMP production.

Preclinical Testing

Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas. Variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation.

Proof-of-Concept

These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability, and cost.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.733.931
Totale projectbegroting€ 2.733.931

Tijdlijn

Startdatum1-4-2023
Einddatum30-6-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SApenvoerder
  • TARGETGENE BIOTECHNOLOGIES LTD
  • UNIVERSIDAD DE SANTIAGO DE COMPOSTELA
  • DEBRECENI EGYETEM
  • STIFTUNG LEIBNIZ-INSTITUT FUR IMMUNTHERAPIE
  • DEBRECENI EGYETEM

Land(en)

PortugalIsraelSpainHungaryGermany

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS

T-FITNESS aims to enhance T cell therapy by preventing exhaustion through miRNA-based circuits and CRISPR/Cas editing, improving treatment efficacy for solid tumors in cancer patients.

€ 4.387.825
EIC Pathfinder

Bottom-up manufacturing of artificial anti-tumor T cells

The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.

€ 3.391.796
EIC Pathfinder

Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapies

The HyperTargIPS-NK project aims to develop a scalable, off-the-shelf NK cell therapy using iPS cells to target and treat lethal cancers like pancreatic cancer, glioblastoma, and AML.

€ 3.798.713
EIC Pathfinder

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

€ 3.644.418
EIC Pathfinder

Functional chemical reprogramming of cancer cells to induce antitumor immunity

The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.

€ 2.966.695

Vergelijkbare projecten uit andere regelingen

ERC Proof of...

Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid Tumors

CAR-T(uning) aims to enhance CAR-T therapy for NSCLC by improving treatment persistence and reducing tumor immunosuppression, paving the way for effective, broadly applicable cancer therapies.

€ 150.000
ERC Advanced...

Targeting of glycosylation pathways to empower CAR-T therapy of solid tumors.

This project aims to enhance CAR-T cell therapy for solid tumors by engineering glycosylation pathways to improve immune response and long-term persistence against immunosuppressive environments.

€ 2.498.435
ERC Starting...

Engineering CAR-T cells to overcome glycosylation-driven tumour resistance

The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.

€ 1.500.000
ERC Consolid...

Synthetic Chimeric Antigen Receptors: Hijacking Nitrenium Ions for Targeting, Therapy and Safety of Next Generation T Cell Therapy

Develop a universal synthetic CAR T cell platform using activatable nitrenium ions to enhance targeting, control T cell function, and improve efficacy against solid tumors.

€ 2.501.154
ERC Starting...

Polyclonal anti-tumor immunity by engineered human T cells

This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.

€ 1.812.500